Abstract is: Hirudin is a naturally occurring peptide in the salivary glands of blood-sucking leeches (such as Hirudo medicinalis) that has a blood anticoagulant property. This is fundamental for the leeches’ habit of feeding on blood, since it keeps a host's blood flowing after the worm's initial puncture of the skin. Hirudin (MEROPS I14.001) belongs to a superfamily (MEROPS IM) of protease inhibitors that also includes haemadin (MEROPS I14.002) and (MEROPS I15).
| P508 | BNCF Thesaurus ID | 45079 |
| P231 | CAS Registry Number | 8001-27-2 |
| P6706 | De Agostini ID | irudina |
| P1417 | Encyclopædia Britannica Online ID | science/hirudin |
| P646 | Freebase ID | /m/06wgkl |
| P11514 | Great Russian Encyclopedia portal ID | girudin-1d1d86 |
| P6366 | Microsoft Academic ID | 2778271848 |
| P10283 | OpenAlex ID | C2778271848 |
| P652 | UNII | MNY7X23SRZ |
| P11143 | WikiProjectMed ID | Hirudin |
| P1343 | described by source | Armenian Soviet Encyclopedia, vol. 6 | Q124737633 |
| P527 | has part(s) | carbon | Q623 |
| nitrogen | Q627 | ||
| P2868 | subject has role | enzyme | Q8047 |
| Q63439594 | 117. Hirudin does not affect the abnormally high thromboxane biosynthesis in homozygous homocystinuria |
| Q43502583 | 125I-labeling of hirudin |
| Q81069187 | 1H NMR assignment and secondary structure of recombinant RGD-hirudin |
| Q56945341 | A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes |
| Q44715578 | A Fast Photometric Assay for the Determination of Hirudin |
| Q71339903 | A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery |
| Q67978582 | A comparative study of recombinant hirudin and standard heparin in the Wessler model |
| Q42626463 | A comparison between the use of recombinant hirudin and heparin during hemodialysis |
| Q71980414 | A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators |
| Q47300350 | A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement |
| Q53595426 | A control switch for prothrombinase: characterization of a hirudin-like pentapeptide from the COOH terminus of factor Va heavy chain that regulates the rate and pathway for prothrombin activation. |
| Q81426261 | A development of LC-MS method combining ultrafiltration and lyophilization for determination of r-RGD-Hirudin in human serum |
| Q52604152 | A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss. |
| Q42279300 | A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons |
| Q79744158 | A functional clotting assay to monitor the hirudin dosage |
| Q41974875 | A hirudin catching ELISA for quantitating the anticoagulant in biological fluids |
| Q74385869 | A hirudin-sensitive, growth-related proteinase from human fibroblasts |
| Q72905477 | A new approach in monitoring recombinant hirudin during cardiopulmonary bypass |
| Q48189919 | A new signal peptide useful for secretion of heterologous proteins from yeast and its application for synthesis of hirudin |
| Q30470837 | A new single-injury model of balloon angioplasty in cholesterol-fed rabbits: beneficial effect of hirudin and comparison with double-injury model |
| Q33333849 | A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study |
| Q42133043 | A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition |
| Q53654431 | A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection. |
| Q36099643 | A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity |
| Q72202424 | A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis |
| Q72262042 | A quantitative thrombin time for determining levels of hirudin and Hirulog |
| Q33332665 | A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device |
| Q71342024 | A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time |
| Q71688624 | A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time |
| Q39996586 | A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma |
| Q72871873 | A simple activity assay for thrombin and hirudin |
| Q73195457 | A strong thrombin-inhibitory prourokinase derivative with sequence elements from hirudin and the human thrombin receptor |
| Q73029142 | A technique to investigate microvascular mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r-hirudin, and G-4120 |
| Q67940854 | A thrombin binding assay for 125I-hirudin |
| Q37630659 | A versatile assay to determine bacterial and host factors contributing to opsonophagocytotic killing in hirudin-anticoagulated whole blood |
| Q72571589 | Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis |
| Q41216655 | Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl |
| Q44518804 | Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis |
| Q54489151 | Acute urticaria caused by subcutaneous recombinant hirudin: evidence for an IgG-mediated hypersensitivity reaction. |
| Q72544896 | Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model |
| Q43882907 | Adenovirus-mediated expression of the anticoagulant hirudin in human islets: a tool to make the islets biocompatible to blood |
| Q33415365 | Adherence of leucocytes to electrically damaged venules in vivo. Effects of iloprost, PGE1, indomethacin, forskolin, BW 755 C, sulotroban, hirudin, and thrombocytopenia |
| Q71184536 | Adrenaline-induced reactions of human platelets in hirudin plasma |
| Q67907332 | Affects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits |
| Q50879445 | Affinity labeling of lysine-149 in the anion-binding exosite of human alpha-thrombin with an N alpha-(dinitrofluorobenzyl)hirudin C-terminal peptide. |
| Q33329612 | Allergy to heparin, heparinoids, and recombinant hirudin. Diagnostic and therapeutic alternatives |
| Q70640770 | Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs |
| Q76477556 | Amino acid composition of hirudin. Identification of the N-terminal residue |
| Q72808552 | An international collaborative study to investigate standardisation of hirudin potency |
| Q36923180 | An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. |
| Q67976386 | Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin |
| Q70840846 | Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results |
| Q93048744 | Anti-atherosclerotic effects between a combined treatment with simvastatin plus hirudin and single simvastatin therapy in patients with early type 2 diabetes mellitus |
| Q73470254 | Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin |
| Q71600682 | Anti-hirudin monoclonal antibodies directed toward discontinuous epitopes of the hirudin amino-terminal and epitopes involving the carboxy-terminal hirudin amino acids |
| Q73926583 | Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife |
| Q74286792 | Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis |
| Q69613000 | Anticoagulant activity of synthetic hirudin peptides |
| Q37123006 | Anticoagulant and Antithrombotic Actions of Recombinant Hirudin |
| Q33358515 | Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis |
| Q69230195 | Anticoagulant peptides: nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site on thrombin |
| Q71254599 | Anticoagulant peptides; synthesis, stability and antithrombin activity of hirudin C-terminal-related peptides and their disulfated analog |
| Q33496183 | Anticoagulant therapy with recombinant hirudin in patients with thrombopenia induced by heparin |
| Q33184946 | Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass |
| Q33332903 | Anticoagulation in extracorporeal circulation using recombinant hirudin: a case report |
| Q33338278 | Anticoagulation with hirudin for continuous veno-venous hemodialysis in liver transplantation |
| Q33379744 | Anticoagulation with hirudin for repeat cardiac surgery in a patient with heparin induced thrombocytopaenia |
| Q33329856 | Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytopenia |
| Q33499644 | Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient |
| Q33345161 | Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients |
| Q33329100 | Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid |
| Q68927195 | Antithrombin activity of the hirudin N-terminal core domain residues 1-43 |
| Q63489872 | Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model |
| Q69721004 | Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N alpha-acetyl-hirudin45-65 |
| Q72379659 | Antithrombin, antitrypsin and antichymotrypsin activities of the salivary gland secretion and intestinal chyme of medicinal leeches. Antichymotrypsin activity of partially purified preparations of hirudin and pseudohirudin |
| Q44917061 | Antithrombotic Action of Recombinant Hirudin in a Venous Thrombosis Model |
| Q67824417 | Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals |
| Q70202684 | Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals |
| Q69711801 | Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin |
| Q43692114 | Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin |
| Q41834459 | Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model |
| Q33266432 | Antithrombotic effects of recombinant hirudin in different animal models |
| Q68417577 | Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis |
| Q73120065 | Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting |
| Q33687800 | Antithrombotic stent coatings: hirudin/iloprost combination |
| Q79399833 | Application of HPLC-ESI-ITMS in the quality control of carboxyterminal sequence confirmation for the recombinant DNA product Hirudin Variant 3 |
| Q45242674 | Argatroban treatment for patients with intolerance to heparin and hirudin |
| Q30469807 | Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model: time course and effect of hirudin |
| Q43936503 | Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration |
| Q100541293 | Artificial intelligence based identification of the functional role of hirudin in diabetic erectile dysfunction treatment |
| Q46377671 | Assay of disulfide oxidase and isomerase based on the model of hirudin folding |
| Q70066031 | Assay of hirudin in plasma using a chromogenic thrombin substrate |
| Q36744975 | Assessment of Multiplate platelet aggregometry using citrate, heparin or hirudin in Rhesus macaques |
| Q33503031 | Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin). |
| Q74286798 | BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban |
| Q70141011 | Basis for the reduced affinity of beta T- and gamma T-thrombin for hirudin |
| Q71574037 | Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen |
| Q72819404 | Binding of fluorescent and spin-labeled C-terminal hirudin analogs to thrombin |
| Q56838414 | Binding of hirudin to human α, β and γ-thrombin |
| Q47851984 | Binding of hirudin to meizothrombin |
| Q68599028 | Binding properties of hirudin determined by gel filtration and gel electrophoresis |
| Q73609668 | Bioactive immobilization of r-hirudin on CVD-coated metallic implant devices |
| Q41186624 | Biochemistry and biology of hirudin. |
| Q38735186 | Biochemistry and genetic engineering of hirudin |
| Q77520113 | Bioengineering of a novel small diameter polyurethane vascular graft with covalently bound recombinant hirudin |
| Q58898563 | Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group |
| Q53551386 | Biological protein-resistance layer construction of recombinant hirudin on polymethyl methacrylate IOL surface. |
| Q34990991 | Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies |
| Q38735182 | Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis |
| Q40737825 | Biophysical studies of interactions of hirudin analogs with bovine and human thrombin by ESR and fluorescence labelling studies |
| Q33361074 | Bivalent direct thrombin inhibitors: hirudin and bivalirudin |
| Q33331350 | Bleeding after intermittent or continuous r-hirudin during CVVH. |
| Q77736088 | Bleeding times and the antithrombotic effects of high-dose aspirin, hirudin and heparins in the rat |
| Q52512986 | C-terminal proteolytic degradation of recombinant desulfato-hirudin and its mutants in the yeast Saccharomyces cerevisiae. |
| Q52389156 | CX-397, a novel recombinant hirudin analog having a hybrid sequence of hirudin variants-1 and -3. |
| Q73349090 | Capillary electrophoresis of r-hirudin and a polyethylene glycol derivative of r-hirudin (PEG-hirudin) |
| Q33339931 | Cardiovascular drug highlight: hirudin. |
| Q33331306 | Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin |
| Q41875010 | Catabolism of hirudin and thrombin-hirudin complexes in the rat. |
| Q102059030 | Cell-free synthesis of the hirudin variant 1 of the blood-sucking leech Hirudo medicinalis |
| Q71543614 | Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding |
| Q42842320 | Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms |
| Q73500562 | Characterization of C-terminal-truncated urinary metabolites of a recombinant hirudin in rats |
| Q53983064 | Characterization of a beta-Asp33 isoform of recombinant hirudin sequence variant 1 by low-energy collision-induced dissociation. |
| Q72706298 | Characterization of succinimide-type dehydration products of recombinant hirudin variant 1 by electrospray tandem mass spectrometry |
| Q68044833 | Characterization of the deamidated forms of recombinant hirudin |
| Q68036130 | Characterization, stability and refolding of recombinant hirudin |
| Q77357257 | Chemical degradation kinetics of recombinant hirudin (HV1) in aqueous solution: effect of pH |
| Q46044142 | Chemical modifications and amino acid substitutions in recombinant hirudin that increase hirudin-thrombin affinity |
| Q44670642 | Chemical synthesis and expression of a gene coding for hirudin, the thrombin-specific inhibitor from the leech Hirudo medicinalis |
| Q45267428 | Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides. |
| Q54787316 | Clinical and experimental studies on the effect of external drugs containing hirudin |
| Q71683515 | Clinical and experimental studies on the effect of hirudin containing externa |
| Q34415399 | Clinical monitoring of hirudin and direct thrombin inhibitors |
| Q71993379 | Clinical pharmacology and drug safety: Lessons from hirudin* |
| Q67976036 | Clinical pharmacology of recombinant hirudin |
| Q41704196 | Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes |
| Q41186629 | Clinical trials of recombinant hirudin in acute coronary syndromes |
| Q69041669 | Clinical use of hirudin |
| Q68026562 | Clinico-pharmacological studies with recombinant hirudin |
| Q34690174 | Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech |
| Q35591074 | Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis |
| Q67453059 | Coagulation inhibition caused by selective thrombin blockade with hirudin |
| Q44275632 | Coexpression of BiP increased antithrombotic hirudin production in recombinant Saccharomyces cerevisiae |
| Q47281359 | College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. |
| Q98227067 | Combination of Quercetin, Hirudin and Cinnamaldehyde Promotes Schwann Cell Differentiation and Myelination against High Glucose by Inhibiting ERK Signaling Pathway |
| Q72841214 | Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumoniae sepsis |
| Q46313390 | Combination of quercetin, cinnamaldehyde and hirudin protects rat dorsal root ganglion neurons against high glucose-induced injury through Nrf-2/HO-1 activation and NF-κB inhibition |
| Q82553147 | Combined administration of barbourin--albumin and hirudin--albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta |
| Q97094688 | Combined optimization of N-terminal site-specific PEGylation of recombinant hirudin using response surface methodology and kinetic analysis |
| Q68148774 | Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model |
| Q47274084 | Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. |
| Q72023596 | Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin |
| Q72027616 | Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems |
| Q67824084 | Comparative studies on various assays for the laboratory evaluation of r-hirudin |
| Q47394694 | Comparative study on the antithrombotic efficacy of hirudin, heparin and a low-molecular weight heparin in preventing experimentally induced venous thrombosis |
| Q72024115 | Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model |
| Q43619560 | Comparative trial of local pharmacotherapy with L-arginine, r-hirudin, and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries |
| Q43289685 | Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests |
| Q73635471 | Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator |
| Q41252958 | Comparison of Commercially Available Blood Collection Tubes Containing Sodium Citrate and Hirudin in Platelet Aggregation Testing |
| Q56944673 | Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention |
| Q70669330 | Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis |
| Q67974582 | Comparison of hirudin and hirudin PA C-terminal fragments and related analogs as antithrombin agents |
| Q41813957 | Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model |
| Q77739539 | Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis |
| Q71769858 | Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins |
| Q73013624 | Comparison of the antithrombotic effects of heparin, hirudin and clopidogrel according to the nature of the thrombogenic surface in an arterioarterial shunt in rats |
| Q67824393 | Comparison of the effects of heparin and hirudin on thrombin binding to the normal and the de-endothelialized rabbit aorta in vitro |
| Q71657023 | Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury |
| Q73606382 | Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators |
| Q52976373 | Comparison of the predictive value of ST segment elevation resolution at 90 and 180 min after start of streptokinase in acute myocardial infarction. A substudy of the hirudin for improvement of thrombolysis (HIT)-4 study. |
| Q77090036 | Comparison of three methods for measuring PEG-hirudin in blood |
| Q70148522 | Comparison of thrombin-antithrombin complex (TAT) levels and fibrinopeptide A following thrombin incubation of human plasma using hirudin as an inhibitor of TAT formation |
| Q33311822 | Comparison of two different methods for the determination of rDNA- hiridin in plasma samples: HPLC vs a chromogenic thrombin substrate |
| Q30703749 | Competitive immunoassay for recombinant hirudin using capillary electrophoresis with laser-induced fluorescence detection |
| Q35743906 | Computational design, functional analysis and antigenic epitope estimation of a novel hybrid of 12 peptides of hirudin and reteplase |
| Q30968769 | Conformational stability of a thrombin-binding peptide derived from the hirudin C-terminus |
| Q43709638 | Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis |
| Q53497899 | Construction and functional evaluation of hirudin derivatives with low bleeding risk. |
| Q73713123 | Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner |
| Q98718952 | Construction of a 3A system from BioBrick parts for expression of recombinant hirudin variants III in Corynebacterium glutamicum |
| Q33235044 | Construction of phage-displayed library by DNA shuffling and the screening of potent hirudin variants |
| Q34223485 | Construction, expression and refolding of a bifunctional fusion protein consisting of C-terminal 12-residue of hirudin-PA and reteplase |
| Q74819361 | Construction, expression, and characterization of recombinant hirudin in Escherichia coli |
| Q33333688 | Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II). |
| Q41822713 | Contribution of interactions with the core domain of hirudin to the stability of its complex with thrombin. |
| Q69438961 | Contribution of the N-terminal region of hirudin to its interaction with thrombin |
| Q79507549 | Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization |
| Q42160965 | Controlling the speed of hirudin folding |
| Q46542769 | Convergent solid-phase synthesis of hirudin |
| Q44110258 | Conversion of recombinant hirudin to the natural form by in vitro tyrosine sulfation. Differential substrate specificities of leech and bovine tyrosylprotein sulfotransferases. |
| Q71936172 | Core domain of hirudin from the leech Hirudinaria manillensis: chemical synthesis, purification, and characterization of a Trp3 analog of fragment 1-47 |
| Q38554206 | Covalent immobilization of hirudin improves the haemocompatibility of polylactide-polyglycolide in vitro |
| Q47693726 | Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity |
| Q73354875 | Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface |
| Q72112490 | Covalent linkage of streptokinase to recombinant hirudin: a novel thrombolytic agent with antithrombotic properties |
| Q27647052 | Crystal Structure of a Biosynthetic Sulfo-hirudin Complexed to Thrombin |
| Q41240502 | Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition |
| Q34485566 | Current status of the anticoagulant hirudin: its biotechnological production and clinical practice |
| Q33334928 | DALI LDL-apheresis: anticoagulation with r-hirudin in a patient with heparin-induced thrombocytopenia (HIT II). |
| Q71242827 | DDAVP reduces bleeding during continued hirudin administration in the rabbit |
| Q70220101 | Deciphering the structural elements of hirudin C-terminal peptide that bind to the fibrinogen recognition site of alpha-thrombin |
| Q50873945 | Decrease of hirudin degradation by deleting the KEX1 gene in recombinant Pichia pastoris. |
| Q33305342 | Degradation of rDNA hirudin and alpha-human thrombin hirudin complex in liver and kidney homogenates from rat. |
| Q33340118 | Delayed cutaneous hypersensitivity reactions to hirudin |
| Q33373731 | Delayed thrombin generation is not associated with fibrinopeptide formation during prolonged cardiopulmonary bypass with hirudin anticoagulation |
| Q33364298 | Delayed thrombin generation with hirudin anticoagulation during prolonged cardiopulmonary bypass |
| Q43841224 | Delayed treatment with desulfato-hirudin prevents fibrin formation in lipopolysaccharide-induced shock |
| Q47243902 | Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin |
| Q71560764 | Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents |
| Q80072448 | Design of a novel plasminogen activator based on the structure of hirudin |
| Q34326984 | Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors |
| Q67947587 | Design, synthesis and antithrombin activity for conformationally restricted analogs of peptide anticoagulants based on the C-terminal region of the leech peptide, hirudin |
| Q71670070 | Desulfated hirugen (hirudin 54-65) induces endothelium-dependent relaxation of porcine pulmonary arteries |
| Q47417233 | Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis |
| Q71843064 | Detection of thrombin in human blood by ex-vivo hirudin |
| Q45292600 | Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin a |
| Q33191811 | Determination of r DNA hirudin and A-human thrombin- hirudin complex in plasma samples: enzyme linked immunosorbent assays for hirudin and complex vs. chromogenic thrombin substrate assay |
| Q67327934 | Determination of r-Hirudin Concentration in the Plasma of Rabbits by Thrombin Time Method |
| Q78707784 | Determination of recombinant hirudin structural deviants by capillary zone electrophoresis augmented with buffer additives |
| Q71947978 | Determination of specific activity of recombinant hirudin using a thrombin titration method |
| Q46326084 | Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons |
| Q70257570 | Determination of the specific activity of recombinant hirudin |
| Q58898578 | Determination of thrombin-hirudin complex in plasma with an enzyme-linked immunosorbent assay |
| Q67329875 | Determnation of r-Hirudin in Urine and Bile of Rabbits by Thrombin Time Method |
| Q72023601 | Development and Validation of Two Enzyme-Linked Immunosorbent Assay (ELISA) Methods for Recombinant Hirudin |
| Q68837651 | Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin |
| Q67826240 | Development of a chromogenic substrate assay for the determination of hirudin in plasma |
| Q74823588 | Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig |
| Q38735170 | Development of hirudin as an antithrombotic agent |
| Q38735189 | Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations |
| Q47833114 | Development, validation, and clinical pharmacokinetic application of ultra-performance liquid chromatography/tandem mass spectrometry method for simultaneously determining a novel recombinant hirudin derivative (Neorudin) and its active metabolite i |
| Q85953327 | Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro |
| Q55489690 | Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase |
| Q73286048 | Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1) |
| Q34196142 | Direct and indirect antithrombins. Heparins, low molecular weight heparins, heparinoids, and hirudin |
| Q33393669 | Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate |
| Q72433867 | Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement |
| Q46718813 | Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin |
| Q77535798 | Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin |
| Q33195600 | Directed evolution towards protease-resistant hirudin variants |
| Q72433870 | Displacement of fibrin-bound thrombin by r-hirudin precludes the use of 131I-r-hirudin for detecting pulmonary emboli in the rabbit |
| Q32141801 | Display of functional thrombin inhibitor hirudin on the surface of phage M13. |
| Q31805452 | Dissociation of multiply charged negative ions for hirudin (54-65), fibrinopeptide B, and insulin A (oxidized). |
| Q66926102 | Dissociation of thrombin from platelets by hirudin. Evidence for receptor processing |
| Q60924339 | Dissolution of Mural Thrombus by Specific Thrombin Inhibition With r-Hirudin |
| Q92320061 | Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays |
| Q71102907 | Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin |
| Q35966108 | Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study |
| Q30472866 | Early plus delayed hirudin reduces restenosis in the atherosclerotic rabbit more than early administration alone: potential implications for dosing of antithrombin agents |
| Q45176859 | Ecarin chromogenic assay--a new method for quantitative determination of direct thrombin inhibitors like hirudin |
| Q77309612 | Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity |
| Q57790565 | Effect of Paclitaxel+Hirudin on the TLR4-MyD88 Signaling Pathway During Inflammatory Activation of Human Coronary Artery Smooth Muscle Cells and Mechanistic Analysis |
| Q44844782 | Effect of chemical modification of hirudin on its inhibition of the enzymatic activity of thrombin |
| Q45797863 | Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin |
| Q69467938 | Effect of heparin on the interaction between thrombin and hirudin |
| Q68536268 | Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats |
| Q40197686 | Effect of hirudin on hormonally caused activation of nonenzymatic fibrinolysis in immobilization stress |
| Q72552830 | Effect of hirudin on platelet deposition to an artificial surface during low-stress shear flow of whole blood |
| Q97095200 | Effect of hirudin on serum matrix metalloproteinase-9 of acute cerebral infarction: A protocol of systematic review and meta-analysis |
| Q67976045 | Effect of hirudin on the chemotactic properties of alpha-thrombin |
| Q83161069 | Effect of hirudin on the levels of acute lung injury rat tumor necrosis factor-α and matrix metalloproteinase-12 |
| Q68385479 | Effect of hirudin on tissue plasminogen activator induced clot lysis |
| Q82228145 | Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials: an in vitro study |
| Q56944551 | Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes |
| Q85899795 | Effect of natural hirudin on random pattern skin flap survival in a porcine model |
| Q67976053 | Effect of recombinant hirudin (LU 52369) on reocclusion rates after thrombolysis in rabbits |
| Q41161357 | Effect of recombinant hirudin on cytosolic Ca2+ concentrations using different platelet stimulators |
| Q41207475 | Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs |
| Q61853544 | Effect of the administration of recombinant hirudin and/or tissue-plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits |
| Q62694018 | Effect of the administration of recombinant hirudin and/or tissue-plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits |
| Q67768931 | Effect of the hirudin carboxy-terminal peptide 54-65 on the interaction of thrombin with platelets |
| Q67592623 | Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin |
| Q90374631 | Effects of Hirudin on High Glucose-Induced Oxidative Stress and Inflammatory Pathway in Rat Dorsal Root Ganglion Neurons |
| Q55379899 | Effects of Natural Hirudin and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis in Aged Patients with Intertrochanteric Fracture. |
| Q28195417 | Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers |
| Q30849704 | Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model |
| Q44112234 | Effects of different methanol feeding strategy on hirudin production in high-density fermentation by recombinant Pichia pastoris |
| Q70897441 | Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma |
| Q52189645 | Effects of hirudin (thrombin specific inhibitor) in zebrafish embryos: a developmental role for thrombin. |
| Q72595299 | Effects of hirudin on activated partial thromboplastin time determined with ten different reagents |
| Q43765081 | Effects of methanol on expression of an anticoagulant hirudin in recombinant Hansenula polymorpha |
| Q42109971 | Effects of natural and recombinant hirudin on VEGF expression and random skin flap survival in a venous congested rat model |
| Q84686506 | Effects of natural and recombinant hirudin on superoxide dismutase, malondialdehyde and endothelin levels in a random pattern skin flap model |
| Q78171073 | Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation |
| Q47351464 | Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin). |
| Q72510847 | Effects of recombinant hirudin on D dimer levels before and after experimental venous thrombosis |
| Q38348175 | Effects of site specific amino acid exchanges in hirudin on the thrombin-hirudin interaction. |
| Q72544899 | Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin |
| Q60924822 | Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor |
| Q77398453 | Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement. HIT-4 Trial Group. Hirudin for Improvement of Thrombolysis |
| Q72338933 | Effects of two different doses of hirudin on APTT, determined with eight different reagents |
| Q47323065 | Effects of unfractionated heparin, low molecular weight heparin and r-hirudin on leukocyte adhesion in ischemia/reperfusion |
| Q44323022 | Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. |
| Q77684350 | Efficacy and safety of topical hirudin (Hirudex): a double-blind, placebo-controlled study |
| Q58375758 | Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention |
| Q46707703 | Efficacy of hirudin in treating immunoglobulin A nephropathy with hematuria: a randomized controlled trial |
| Q74619315 | Efficient expression and secretion of recombinant hirudin III in E. coli using the L-asparaginase II signal sequence |
| Q73633060 | Efficient synthesis of the blood-coagulation inhibitor hirudin in the filamentous fungus Acremonium chrysogenum |
| Q52298901 | Electrostatic interactions in hirudin-thrombin binding. |
| Q41765295 | Electrostatic interactions in the association of proteins: an analysis of the thrombin-hirudin complex |
| Q73762746 | Electrostatic steering and ionic tethering in the formation of thrombin-hirudin complexes: the role of the thrombin anion-binding exosite-I |
| Q33333260 | Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems |
| Q79210085 | Elucidation of the disulfide-folding pathway of hirudin by a topology-based approach |
| Q33503721 | Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin |
| Q55652383 | Endotoxin-induced capillary perfusion failure and leukocyte adhesion is not prevented by the thrombin inhibitor hirudin: an intravital microscopic study. |
| Q61853545 | Endotoxin-induced disseminated intravascular coagulation in rabbits: Effect of recombinant hirudin on hemostatic parameters, fibrin deposits, and mortality |
| Q98469432 | Enhanced Anticoagulant Activity of Hirudin-I Analogue Co-expressed with Arylsulfotransferase in Periplasm of E. coli BL21(DE3) |
| Q73410307 | Enhanced production of anticoagulant hirudin in recombinant Saccharomyces cerevisiae by chromosomal delta-integration |
| Q33298030 | Enhanced secretion of adhesive recognition sequence containing hirudin III mutein in E. coli |
| Q73263102 | Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model |
| Q38338187 | Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. |
| Q88869683 | Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics |
| Q47887270 | Evaluation of a novel hirudin-coated polyester graft to physiologic flow conditions: hirudin bioavailability and thrombin uptake |
| Q49224835 | Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma |
| Q58710785 | Evaluation of drug release from paclitaxel + hirudin-eluting balloons and the resulting vascular reactivity in healthy pigs |
| Q41162582 | Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study |
| Q69215660 | Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis |
| Q51694068 | Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. |
| Q45205516 | Evidence for the identity of hirudin isolated after kidney passage with the starting material |
| Q62694065 | Evidence that Heparin but Not Hirudin Reduces PAI-1 Expression in Cultured Human Endothelial Cells |
| Q43819282 | Existence of beta-methylnorleucine in recombinant hirudin produced by Escherichia coli |
| Q72916484 | Experiences with hirudin in the intracutaneous treatment of superficial thrombophlebitis |
| Q70202668 | Experimental studies on a recombinant hirudin, CGP 39393 |
| Q40988724 | Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis |
| Q46548707 | Expression of recombinant Hirudin in transgenic mice milk driven by the goat beta-casein promoter |
| Q39992790 | Expression of recombinant anticoagulant hirudin in the differentiated cultures of the porcine mammary epithelial cell line SI-PMEC. |
| Q70779943 | Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in Saccharomyces cerevisiae |
| Q31081745 | Expression, purification, and mass spectrometric analysis of 15N, 13C-labeled RGD-hirudin, expressed in Pichia pastoris, for NMR studies |
| Q54778005 | Expression, secretion and processing of hirudin in E. coli using the alkaline phosphatase signal sequence. |
| Q34013880 | Extracellular secretion of anticoagulant peptide hirudin in Lactococcus lactis using SP310mut2 signal peptide |
| Q40846447 | Factor X fusion proteins: improved production and use in the release in vitro of biologically active hirudin from an inactive alpha-factor-hirudin fusion protein |
| Q72711487 | Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin |
| Q72315490 | Flow cytometric evaluation of platelet activation by ionic or nonionic contrast media and modulation by heparin and recombinant hirudin |
| Q72118445 | Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin |
| Q74063271 | Formulation of sustained release aqueous Zn-hirudin suspensions |
| Q71551077 | Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group |
| Q71248794 | Further experimental studies on the effect of a hirudin-containing ointment |
| Q35038471 | Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition |
| Q41120821 | Future alternatives to heparin: Low-molecular-weight heparin and hirudin |
| Q79279714 | Gastrointestinal Absorption of Recombinant Hirudin-2 in Rats |
| Q77905441 | General numerical treatment of competitive binding kinetics: application to thrombin-dehydrothrombin-hirudin |
| Q33330227 | Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. |
| Q47995438 | Glow discharge plasma deposition (GDPD) technique for the local controlled delivery of hirudin from biomaterials |
| Q77117098 | HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte |
| Q76656245 | HIRUDIN AND PELENTAN IN THE TREATMENT OF RETINAL VEIN THROMBOSIS |
| Q76847266 | HIRUDIN, A PROVING (HYGANTHROPHARMACOLOGY) |
| Q67510880 | Haemostyptic effects of batroxobin with regard to hirudin treatment |
| Q53040014 | Hemocompatibility and cytocompatibility of the hirudin-modified silk fibroin. |
| Q33376243 | Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use. |
| Q47427232 | Heparin and low molecular weight heparin but not hirudin stimulate platelet aggregation in whole blood from acetylsalicylic acid treated healthy volunteers |
| Q67585239 | Heparin enhances platelet aggregation irrespective of anticoagulation with citrate or with hirudin |
| Q68014428 | Heparin today, hirudin tomorrow? |
| Q56945288 | Heparin versus Hirudin for Acute Coronary Syndromes |
| Q93554321 | Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy |
| Q74245140 | Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin) |
| Q33366886 | Heparin-induced thrombocytopenia and the use of r-hirudin during cardiopulmonary bypass. |
| Q33338766 | Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin |
| Q73902638 | Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin |
| Q33333174 | Heparin-induced thrombocytopenia: a critical risk/benefit analysis of patients in intensive care treated with R-hirudin. |
| Q33377535 | Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. |
| Q73579084 | High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery |
| Q46452324 | High cell density cultivation of recombinant E. coli for hirudin variant 1 production by temperature shift controlled by pUC18-based replicative origin |
| Q53496469 | High cell density cultivation of recombinant Escherichia coli for hirudin variant 1 production. |
| Q70992073 | High-level secretion of hirudin by Hansenula polymorpha--authentic processing of three different preprohirudins |
| Q81414822 | Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma |
| Q67824090 | Hirudin |
| Q68237033 | Hirudin |
| Q72574227 | Hirudin |
| Q33503948 | Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study |
| Q45019916 | Hirudin (desulfated, 54-65) contracts canine coronary arteries: extracellular calcium influx mediates hirudin-induced contractions |
| Q97884001 | Hirudin Ameliorates Renal Interstitial Fibrosis via Regulating TGF-β1/Smad and NF-κB Signaling in UUO Rat Model |
| Q68230420 | Hirudin C-terminal fragments inhibit thrombin induced neutrophil chemotaxis |
| Q71200405 | Hirudin CGP 39393 as thromboprophylaxis |
| Q98733770 | Hirudin Protects Against Kidney Damage in Streptozotocin-Induced Diabetic Nephropathy Rats by Inhibiting Inflammation via P38 MAPK/NF-κB Pathway |
| Q58757711 | Hirudin Protects Ang II-Induced Myocardial Fibroblasts Fibrosis by Inhibiting the Extracellular Signal-Regulated Kinase1/2 (ERK1/2) Pathway |
| Q96026212 | Hirudin Reduces the Expression of Markers of the Extracellular Matrix in Renal Tubular Epithelial Cells in a Rat Model of Diabetic Kidney Disease Through the Hypoxia-Inducible Factor-1α (HIF-1α)/Vascular Endothelial Growth Factor (VEGF) Signaling Pa |
| Q64082489 | Hirudin ameliorates immunoglobulin A nephropathy by inhibition of fibrosis and inflammatory response |
| Q81022430 | Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure |
| Q92515546 | Hirudin and Decorsins of the North American Medicinal Leech Macrobdella decora: Gene Structure Reveals Homology to Hirudins and Hirudin-like Factors of Eurasian Medicinal Leeches |
| Q40466073 | Hirudin and Excess Bleeding Implications For Future Use |
| Q72325104 | Hirudin and Hirulog |
| Q36916957 | Hirudin and Platelets |
| Q68022180 | Hirudin and derivatives as anticoagulant agents |
| Q82077379 | Hirudin and heparin enable efficient megakaryocyte differentiation of mouse bone marrow progenitors |
| Q41644774 | Hirudin and hirudin analogues as new anticoagulant agents |
| Q67827150 | Hirudin and hirudin fragments |
| Q52406317 | Hirudin and hirudin-based peptides. |
| Q78435397 | Hirudin and its reversal |
| Q50803377 | Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta. |
| Q47772115 | Hirudin and other thrombin inhibitors experimental results and potential clinical applications |
| Q68055205 | Hirudin and restenosis |
| Q85554929 | Hirudin and s18886 maintain luminal patency after thrombolysis with alfimeprase |
| Q67919049 | Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis |
| Q70989300 | Hirudin and thrombosis prophylaxis |
| Q51277912 | Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay. |
| Q78466512 | Hirudin anticoagulation for CPB |
| Q38192929 | Hirudin as a diagnostic agent |
| Q36133849 | Hirudin as a molecular probe for thrombin in vitro and during systemic coagulation in the pig. |
| Q40354509 | Hirudin as a novel fusion tag for efficient production of lunasin in Escherichia coli |
| Q34158069 | Hirudin as alternative anticoagulant--a historical review |
| Q42114932 | Hirudin as an anticoagulant for both haematology and chemistry tests |
| Q33331358 | Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function |
| Q67976041 | Hirudin as anticoagulant in experimental hemodialysis |
| Q81795618 | Hirudin binding reveals key determinants of thrombin allostery |
| Q44938284 | Hirudin binding to soluble dextran. |
| Q77295099 | Hirudin causes more bleeding than heparin in a rabbit ear bleeding model |
| Q33334867 | Hirudin determination in plasma can be strongly influenced by the prothrombin level |
| Q56896706 | Hirudin display on the surface of bacteriophage M13 |
| Q33330588 | Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. |
| Q37305524 | Hirudin for diagnostic purposes |
| Q33387634 | Hirudin for management of heparin-induced thrombocytopenia type II in a patient with biventricular assist device support |
| Q34990987 | Hirudin for prophylaxis and treatment of deep vein thrombosis |
| Q71016304 | Hirudin from leech heads and whole leeches and "pseudo-hirudin" from leech bodies |
| Q89745104 | Hirudin improves renal interstitial fibrosis by reducing renal tubule injury and inflammation in unilateral ureteral obstruction (UUO) mice |
| Q40908310 | Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense |
| Q73295828 | Hirudin in Acute Myocardial Infarction |
| Q33345166 | Hirudin in acute coronary syndromes |
| Q72711397 | Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial |
| Q71493537 | Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial |
| Q28333153 | Hirudin in disseminated intravascular coagulation |
| Q70257575 | Hirudin in haemodialysis |
| Q33345155 | Hirudin in heparin-induced thrombocytopenia |
| Q33345169 | Hirudin in renal insufficiency |
| Q72823817 | Hirudin in the treatment of arterial and venous thrombotic diseases: a new perspective |
| Q43072456 | Hirudin inhibits cell growth via ERK/MAPK signaling in human glioma |
| Q70079764 | Hirudin insensitive thrombin-stimulated platelet release |
| Q28334822 | Hirudin interruption of heparin-resistant arterial thrombus formation in baboons |
| Q82092183 | Hirudin is modestly more effective than heparin in the treatment of acute coronary syndromes |
| Q73350252 | Hirudin is superior to heparin in reducing cardiovascular mortality, infarct and refractory angina in patients with unstable angina or myocardial infarct without elevation of the ST tract |
| Q33333086 | Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II. |
| Q91304613 | Hirudin or hirudin-like factor - that is the question: insights from the analyses of natural and synthetic HLF variants |
| Q104510483 | Hirudin prevents vascular endothelial cell apoptosis and permeability enhancement induced by the serum from rat with chronic renal failure through inhibiting RhoA/ROCK signaling pathway |
| Q54273104 | Hirudin promotes angiogenesis by modulating the cross-talk between p38 MAPK and ERK in rat ischemic skin flap tissue. |
| Q96587527 | Hirudin protects against isoproternol-induced myocardial infraction by alleviating oxidative via an Nrf2 dependent manner |
| Q43658061 | Hirudin protects from leukocyte/endothelial cell interaction induced by extracorporeal circulation |
| Q94953680 | Hirudin reduces nephropathy microangiopathy in STZ-induced diabetes rats by inhibiting endothelial cell migration and angiogenesis |
| Q30651478 | Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts |
| Q77133120 | Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries |
| Q71679553 | Hirudin stimulates prostacyclin but not endothelin-1 production in cultured human vascular endothelial cells |
| Q48578175 | Hirudin suppresses the invasion of inflammatory cells and the appearance of vimentin-positive astrocytes in the rat cerebral ablation model |
| Q33336136 | Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia |
| Q57428671 | Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia |
| Q33493951 | Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis |
| Q50173074 | Hirudin tolerance test following an operative trauma and during the postoperative period |
| Q80250450 | Hirudin treatment for multiple thromboses in a preterm infant with inherited thrombophilia |
| Q73858349 | Hirudin treatment in a breastfeeding woman |
| Q57134806 | Hirudin variants production by genetic engineered microbial factory |
| Q47281565 | Hirudin versus heparin and low-molecular-weight heparin: and the winner is... |
| Q52963863 | Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. |
| Q81251776 | Hirudin versus heparin for use in whole blood in vitro biocompatibility models |
| Q56638592 | Hirudin – the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond |
| Q37361388 | Hirudin, a new therapeutic tool? |
| Q70251824 | Hirudin, a probe to analyze the growth-promoting activity of thrombin in fibroblasts; reevaluation of the temporal action of competence factors |
| Q34369110 | Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis |
| Q67902811 | Hirudin--a potential stabilizing factor for platelet preservation in transfusion |
| Q43815106 | Hirudin--comeback of Hirudo medicinalis |
| Q33335681 | Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting |
| Q33367403 | Hirudin-based anticoagulant strategy during isolated limb perfusion in a patient with heparin-induced thrombocytopenia |
| Q67296087 | Hirudin-based peptides block the inflammatory effects of thrombin on endothelial cells |
| Q40617302 | Hirudin-based synthetic peptides as inhibitors of thrombin |
| Q43251667 | Hirudin-induced pseudothrombocytopenia in a patient with EDTA-dependent platelet aggregation: report of a new laboratory artefact |
| Q68021245 | Hirudin. A new and promising anticoagulant from leech |
| Q73286001 | Hirudin: Its Biology and Clinical Use |
| Q35109753 | Hirudin: a family of iso-proteins. Isolation and sequence determination of new hirudins. |
| Q44666123 | Hirudin: amino-terminal residues play a major role in the interaction with thrombin |
| Q40759605 | Hirudin: clinical potential of a thrombin inhibitor |
| Q40541708 | Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty |
| Q72556240 | Hirudin: long live the leech! |
| Q40737786 | Hirudin: the famous anticoagulant agent. |
| Q36175583 | Hirudins and hirudin-like factors in Hirudinidae: implications for function and phylogenetic relationships |
| Q52408328 | Hirudisins. Hirudin-derived thrombin inhibitors with disintegrin activity |
| Q36280837 | Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex |
| Q74379420 | Hirunorms, novel hirudin-like direct thrombin inhibitors |
| Q58836913 | Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins |
| Q90581505 | Identification and characterization of hirudin-HN, a new thrombin inhibitor, from the salivary glands of Hirudo nipponia |
| Q69417412 | Identification of regions of alpha-thrombin involved in its interaction with hirudin |
| Q45044572 | Immobilization of the thrombin inhibitor r-hirudin conserving its biological activity |
| Q47853760 | Immobilized hirudin and hirudin-based peptides used for the purification of recombinant human thrombin prepared from recombinant human prothrombin |
| Q33329712 | Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. |
| Q67976930 | Impact of protein-protein contacts on the conformation of thrombin-bound hirudin studied by comparison with the nuclear magnetic resonance solution structure of hirudin(1-51) |
| Q81094102 | Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome |
| Q46981856 | Improvement of cell viability and hirudin production by ascorbic acid in Pichia pastoris fermentation |
| Q51642369 | Improvement of recombinant hirudin production by controlling NH4+ concentration in Pichia pastoris fermentation. |
| Q99371151 | Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug |
| Q41951405 | In silico designing of a new cysteine analogue of hirudin variant 3 for site specific PEGylation. |
| Q72732692 | In vitro effect of hirudin on recalcification time |
| Q33344968 | In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes |
| Q33330678 | In vitro study of r-hirudin permeability through membranes of different haemodialysers |
| Q77298765 | In vivo analysis of antithrombotic effectiveness of recombinant hirudin on microvascular thrombus formation and recanalization |
| Q73560137 | In vivo assessment of a novel dacron surface with covalently bound recombinant hirudin |
| Q74290909 | In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris |
| Q51599695 | In-vitro antileishmanial potential of peptide drug hirudin. |
| Q36281273 | Incorporation of noncoded amino acids into the N-terminal domain 1-47 of hirudin yields a highly potent and selective thrombin inhibitor. |
| Q36519387 | Incorporation of the fluorescent amino acid 7-azatryptophan into the core domain 1-47 of hirudin as a probe of hirudin folding and thrombin recognition |
| Q46635565 | Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes |
| Q42653563 | Increased backbone flexibility in threonine45-phosphorylated hirudin upon pH change |
| Q68557140 | Influence of chain shortening on the inhibitor properties of hirudin and eglin c |
| Q73579096 | Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin |
| Q52970009 | Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. |
| Q71510196 | Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model |
| Q71397409 | Influence of hirudin on endotoxin-induced disseminated intravascular coagulation (DIC) in weaned pigs |
| Q46494940 | Influence of hirudin on the consumption of antithrombin III in experimental DIC. |
| Q69041665 | Influence of hirudin on the thrombin-induced release of tissue plasminogen activator from isolated perfused pig ear |
| Q71814980 | Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393) |
| Q28319752 | Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems |
| Q71688620 | Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits |
| Q70142863 | Influence of storage conditions on the activity of recombinant hirudin |
| Q68534730 | Influence of the second and third codon on the expression of recombinant hirudin in E. coli |
| Q67874390 | Influence of yeast proteases on hirudin expression in Saccharomyces cerevisiae |
| Q71014952 | Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857 |
| Q72639019 | Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma |
| Q33403139 | Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. |
| Q71788303 | Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46???6240), recombinant hirudin and heparin in human plasma |
| Q78339537 | Inhibition of fluid phase and clot-bound thrombin by the thrombin exosite I ligand LU 58463: comparison with heparin and hirudin |
| Q53779459 | Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor. |
| Q72057049 | Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide |
| Q33360670 | Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium |
| Q40772180 | Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost |
| Q47324262 | Inhibition of neointimal proliferation after coronary angioplasty by low-molecular-weight heparin (clivarine) and polyethyleneglycol-hirudin |
| Q71392199 | Inhibition of the thrombin-platelet reaction by hirudin |
| Q71953600 | Inhibition of thrombin by hirudin genetically fused to wild-type or mutant antithrombin |
| Q68582005 | Inhibition of thrombin by synthetic hirudin peptides |
| Q43775350 | Inhibitory effect of hirudin on thrombosis induced by prothrombin complex concentrates. |
| Q54372385 | Inhibitory effect of r-hirudin variant III on streptozotocin-induced diabetic cataracts in rats. |
| Q72360950 | Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial |
| Q72750413 | Interaction of alpha 2-macroglobulin-bound thrombin with hirudin |
| Q44677934 | Interaction of hirudin with the dysthrombins Quick I and II. |
| Q68045071 | Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity |
| Q52571430 | Interaction of site specific hirudin variants with alpha-thrombin. |
| Q44913179 | Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin |
| Q71881849 | Interactions of hirudin-based inhibitor with thrombin: critical role of the IleH59 side chain of the inhibitor |
| Q33311824 | Interference of heparin and analogues with hirudin in the chromogenic thrombin substrate assay |
| Q33400980 | Interference of thrombin in immunological assays for hirudin specific antibodies |
| Q33362516 | Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy |
| Q46232372 | Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: role of recombinant hirudin variant III. |
| Q73654713 | Intraocular injection of recombinant hirudin to prevent experimental postoperative fibrin |
| Q73169422 | Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin |
| Q45020709 | Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin |
| Q71738880 | Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models |
| Q54589184 | Investigation on minor degraded derivatives of the recombinant hirudin variant HM2 from Hirudinaria manillensis isolated by isoelectric focusing in multicompartment electrolyzers. |
| Q82516880 | Investigation on recombinant hirudin via oral route |
| Q53220235 | Investigation on the microcirculation effect of local application of natural hirudin on porcine random skin flap venous congestion. |
| Q42860116 | Ionic interactions in the formation of the thrombin-hirudin complex |
| Q43051130 | Is hirudin a potential therapeutic agent for arthritis? |
| Q46002413 | Is the ecarin clotting time (ECT) a valid monitoring parameter for r-hirudin-based anticoagulation in continuous renal replacement therapy? |
| Q36917049 | Isolation and characterization of hirudin from Hirudo medicinalis |
| Q69636723 | Isolation and characterization of hirudin isoinhibitors and sequence analysis of hirudin PA |
| Q71987833 | Isolation of hirudin from medicinal leech |
| Q57713304 | Isolation of recombinant hirudin by preparative high-performance liquid chromatography |
| Q73104015 | Kinetic studies of the regeneration of recombinant hirudin variant 1 with oxidized and reduced dithiothreitol |
| Q52630061 | Kinetics of the inhibition of thrombin by hirudin. |
| Q67976050 | Laboratory assays for the evaluation of recombinant hirudin |
| Q36710237 | Laboratory use of hirudin |
| Q72029804 | Leeching, hirudin, and coagulation tests |
| Q33329695 | Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. |
| Q68070246 | Ligation-free gene synthesis by PCR: synthesis and mutagenesis at multiple loci of a chimeric gene encoding OmpA signal peptide and hirudin |
| Q68203610 | Ligation-free gene synthesis by PCR: synthesis and mutagenesis at multiple loci of a chimeric gene encoding ompA signal peptide and hirudin |
| Q70146962 | Liquid secondary ion mass spectrometry applied to structural confirmation of enzymically prepared C-terminal-truncated derivatives of recombinant hirudin |
| Q64382923 | Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury |
| Q30304454 | Local adenovirus-mediated delivery of hirudin in a rabbit arterial injury model |
| Q60924458 | Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty |
| Q70076279 | Local hirudin application--an aid in preventing occlusion of an arteriovenous fistula in dialysis patients? |
| Q33335380 | Long-term anticoagulation with recombinant hirudin in a patient on left ventricular assist device support |
| Q33342137 | Management of HIT II patients with hirudin antibodies after primary therapy |
| Q33331153 | Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin |
| Q33335679 | Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin |
| Q33359993 | Management of phlegmasia alba dolens using hirudin in a neurosurgical patient with heparin-induced thrombocytopenia |
| Q72326679 | Mapping of the thrombin des-ETW conformation by using site-directed mutants of hirudin. Evidence for the induction of nonlocal modifications by mutagenesis |
| Q71242790 | Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement |
| Q68189904 | Mechanism of the inhibition of alpha-thrombin by hirudin-derived fragments hirudin(1-47) and hirudin(45-65) |
| Q53392392 | Medical and surgical uses of recombinant hirudin: an international discussion forum. Munich, Germany, June 26, 1991. |
| Q82092846 | Medium-dose hirudin was superior to heparin in preventing ischemic events in patients with acute myocardial ischemia |
| Q36917066 | Methods for Determination of Hirudin |
| Q78941226 | Microdetermination of an anti-thrombic activity: hirudin |
| Q72791442 | Migration and adhesiveness of human and rabbit blood leukocytes under the influence of metabolic blocking agents and hirudin |
| Q33369804 | Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery |
| Q68186295 | Modulation of thrombin-hirudin interaction by specific ion effects |
| Q40737817 | Molecular basis for the inhibition of thrombin by hirudin |
| Q72653537 | Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays |
| Q33343471 | Monitoring hirudin anticoagulation in two patients undergoing cardiac surgery with a plasma-modified act method |
| Q33344834 | Monitoring of hirudin therapy with the Thrombelastograph |
| Q33499495 | Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time. |
| Q28242881 | Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay |
| Q35743761 | More than just one: multiplicity of Hirudins and Hirudin-like Factors in the Medicinal Leech, Hirudo medicinalis |
| Q36857390 | NMR solution structure of a novel hirudin variant HM2, N-terminal 1-47 and N64-->V + G mutant |
| Q30980122 | Nanoscaled polyion complex micelles for targeted delivery of recombinant hirudin to platelets based on cationic copolymer |
| Q81572437 | Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies |
| Q43122573 | Natural Hirudin Increases Rat Flap Viability by Anti-Inflammation via PARs/p38/NF-κB Pathway |
| Q44621233 | Neutralization of hirudin anticoagulant action by DIP-thrombin. |
| Q36917000 | Neutralization of recombinant hirudin: some practical considerations |
| Q72289362 | New N alpha-guanidinobenzoyl derivatives of hirudin-54-65 containing stabilized carboxyl or phosphoryl groups on the side chain of phenylalanine-63 |
| Q68316046 | New aspects on hirudin. Proceedings of the 1st International Symposium on Hirudin. Frankfurt, June 23-24, 1989 |
| Q47259138 | Non-Coded amino acids in protein engineering: structure-activity-relationship studies of hirudin-thrombin interaction. |
| Q52062836 | Non-invasive detection of early infarct vessel patency by resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction; results of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 t |
| Q30417953 | Novel hirudin variants from the leech Hirudinaria manillensis. Amino acid sequence, cDNA cloning and genomic organization |
| Q54459217 | Novel method of expression and purification of hirudin based on pBAD TOPO, pTYB12 vectors and gene synthesis. |
| Q27642095 | Nuclear magnetic resonance solution structure of hirudin(1-51) and comparison with corresponding three-dimensional structures determined using the complete 65-residue hirudin polypeptide chain |
| Q50732665 | O(ON THE STANDARDIZATION OF HIRUDIN TRADE PREPARATIONS) |
| Q33364740 | Off-pump coronary artery bypass grafting in a heparin-induced thrombocytopenia type II patient using hirudin |
| Q40793522 | On Hirudin and Hirudin Immunity |
| Q47985506 | On the NH 2 -terminal residue of hirudin |
| Q53801110 | On the isolation of the thrombin inhibitor hirudin. |
| Q83217336 | Online preconcentration of recombinant Arg-Gly-Asp-hirudin using dynamic pH junction for analysis in human urine samples by capillary electrophoresis-mass spectrometry |
| Q45007042 | Optimization of expression of an annexin V-hirudin chimeric protein in Escherichia coli |
| Q72275349 | Optimization of the expression system using galactose-inducible promoter for the production of anticoagulant hirudin in Saccharomyces cerevisiae |
| Q46416624 | Optimizing management of hirudin anticoagulation |
| Q44923632 | Our experiences with the hirudin test for the continuous control of prothrombin activity |
| Q84182191 | Overproduction of 15N-labeled r-RGD-hirudin in pichia pastoris for NMR studies |
| Q42126977 | Oxidative folding of hirudin in human serum |
| Q51207791 | PEG-hirudin/iloprost coating of small diameter ePTFE grafts effectively prevents pseudointima and intimal hyperplasia development. |
| Q37305504 | Past, present and future of hirudin |
| Q83370024 | Pathway of oxidative folding of a 3-disulfide alpha-lactalbumin may resemble either BPTI model or hirudin model |
| Q46753500 | Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo |
| Q72893501 | Persistent thrombin generation in humans during specific thrombin inhibition with hirudin |
| Q73418225 | Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers |
| Q73293249 | Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure |
| Q57369814 | Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes |
| Q33191812 | Pharmacokinetic investigations of the alpha-human thrombin-hirudin complex in rhesus monkeys |
| Q54130949 | Pharmacokinetic studies with recombinant hirudin in dogs. |
| Q34493205 | Pharmacokinetic study with N-Ile1-Thr2-63-desulfato-r-hirudin in rabbits by means of bioassay |
| Q52431805 | Pharmacokinetics and anticoagulant effect of hirudin in man. |
| Q74786976 | Pharmacokinetics and partial thromboplastin time after intravenous recombinant hirudin variant-2 in rhesus monkeys |
| Q52426744 | Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. |
| Q44836126 | Pharmacokinetics of 125I-hirudin in rats and dogs. |
| Q36917034 | Pharmacokinetics of Hirudin |
| Q42687700 | Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration |
| Q47901180 | Pharmacokinetics of recombinant hirudin in healthy horses |
| Q50034825 | Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients |
| Q34778597 | Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays |
| Q52423429 | Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man. |
| Q28370722 | Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban |
| Q34733975 | Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin |
| Q70439861 | Pharmacological studies on the antithrombotic action of hirudin in experimental animals |
| Q48101571 | Pharmacological survey of recombinant hirudin |
| Q38410604 | Pharmacology and controlled release of hirudin for cardiovascular disorders |
| Q41706867 | Pharmacology and therapeutic applications of hirudin, a new anticoagulant |
| Q69924781 | Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent in medicinal leeches |
| Q68037221 | Pharmacology of r-hirudin in renal impairment |
| Q34990977 | Pharmacology of recombinant hirudin |
| Q69073131 | Plasma level of dextran-r-hirudin |
| Q67998260 | Platelet aggregation in recombinant-hirudin-anticoagulated blood |
| Q71335943 | Platelet aggregation, sensitivity to prostaglandin E1 and thromboxane A2 release in recombinant hirudin- and heparin-anticoagulated blood |
| Q73700303 | Platelet aggregatory responses to low-dose collagen are maintained in hirudin-anticoagulated whole blood for 24 h when stored at room temperature |
| Q72066929 | Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin |
| Q53281424 | Platelet function testing in hirudin and BAPA anticoagulated blood. |
| Q68839183 | Platelet functions in recombinant hirudin-anticoagulated blood |
| Q45742588 | Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin |
| Q34060457 | Poly(lactic-co-glycolic) acid microspheres encapsulated in Pluronic F-127 prolong hirudin delivery and improve functional recovery from a demyelination lesion |
| Q70114924 | Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptides |
| Q36857463 | Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. |
| Q33327449 | Potential use of hirudin in diabetic cataract: a study of galactose mediated human lens epithelial cells injury |
| Q68186472 | Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model |
| Q69075720 | Preparation of antibodies to a synthetic C terminus of hirudin and identification of an antigenic site |
| Q67685648 | Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour |
| Q45083166 | Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin-thrombin interaction |
| Q67980007 | Preparation of monoclonal antibodies to the thrombin/hirudin complex |
| Q51351756 | Preparation, characterization and in vivo observation of phospholipid-based gas-filled microbubbles containing hirudin. |
| Q69041659 | Present problems in haemostaseology. Part I: Hirudin, LMW-heparin and other antithrombotic agents. The Vth international meeting of the Danubian League against Thrombosis and Haemorrhagic Disorders in conjunction with the 16th Erfurt Conference on H |
| Q47237532 | President's page: new medicine from old--hirudin and the leech |
| Q74582616 | Pretreatment of rabbits with either hirudin, ancrod, or warfarin significantly reduces the immediate uptake of fibrinogen and platelets by the deendothelialized aorta wall after balloon-catheter injury in vivo |
| Q47355233 | Prevention of Experimental Venous Thrombosis in Rabbits with Different Low Molecular Weight Heparins, Dermatan Sulphate and Hirudin |
| Q45016452 | Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. |
| Q71563162 | Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin |
| Q69041714 | Prevention of experimental coronary thrombosis by hirudin |
| Q83023580 | Prevention of hyperacute xenograft rejection through direct thrombin inhibition with hirudin |
| Q71616589 | Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin |
| Q53361381 | Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. |
| Q33332969 | Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study |
| Q33372196 | Primary structure determination of hirudin and reteplase fusion protein by LC/ESI-MS/MS spectrometry |
| Q67874388 | Probing the distance between the two binding sites of hirudin for its interaction with the active site and the fibrin(ogen)-binding site of alpha-thrombin |
| Q42687739 | Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation |
| Q71989218 | Probing the structure of hirudin from Hirudinaria manillensis by limited proteolysis. Isolation, characterization and thrombin-inhibitory properties of N-terminal fragments |
| Q67345314 | Proceedings: Complete primary structure of prothrombin. Partial primary structures of plasminogen and hirudin |
| Q34174507 | Production and characterization of hirudin variant-1 by SUMO fusion technology in E. coli |
| Q34362567 | Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin. |
| Q38735178 | Production and evaluation of recombinant hirudin |
| Q71859628 | Production and purification of recombinant hirudin expressed in the methylotrophic yeast Pichia pastoris |
| Q44817298 | Production of antithrombotic hirudin in GAL1-disrupted Saccharomyces cerevisiae |
| Q71045586 | Production of biologically active hirudin in plant seeds using oleosin partitioning |
| Q72659541 | Production of disulfide-linked hirudin dimer by in vitro folding |
| Q72272968 | Production of recombinant hirudin by high cell density fed-batch cultivations of a Saccharomyces cerevisiae strain: physiological considerations during the bioprocess design |
| Q36923177 | Production of the HV1 variant of hirudin by recombinant DNA methodology |
| Q34638782 | Production, properties, and thrombin inhibitory mechanism of hirudin amino-terminal core fragments. |
| Q70148236 | Profibrinolytic activity of recombinant hirudin? |
| Q33335730 | Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study |
| Q78257144 | Prolonged bleeding after cardiopulmonary bypass with recombinant hirudin in heart transplantation |
| Q30717140 | Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris. |
| Q39396376 | Protective effect of recombinant hirudin variant III against galactose-mediated rat lens epithelial cell damage |
| Q47837878 | Proteolysis of human factor II by factor Xa in the presence of hirudin |
| Q70960575 | Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin |
| Q30604793 | Proton bridging in the interactions of thrombin with hirudin and its mimics |
| Q57904993 | Proton nuclear magnetic resonance study of hirudin: resonance assignment and secondary structure |
| Q33366573 | Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure |
| Q53878501 | Purification and analysis of the thrombin inhibitor hirudin |
| Q54731380 | Purification and biochemical characterization of recombinant hirudin produced by Saccharomyces cerevisiae. |
| Q51605553 | Purification and identification of recombinant hirudin and its degradation products expressed in Pichia pastoris. |
| Q39143577 | Purification of hirudin by the method of isoelectric focusing |
| Q71366366 | Qualitative and quantitative detection of human and recombinant thrombin by binding to leech and recombinant hirudin immobilized at the solid phase |
| Q74182620 | Quantitative determination of PEG-hirudin in human plasma using a competitive enzyme-linked immunosorbent assay |
| Q71533351 | Quantitative determination of hirudin in blood and body fluids |
| Q70018756 | Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin |
| Q52523504 | Quantitative evaluation of the contribution of ionic interactions to the formation of the thrombin-hirudin complex. |
| Q33333165 | R-hirudin (lepirudin, refludan) as an alternative anticoagulant in heparin-induced thrombocytopenia during cardiopulmonary bypass connection |
| Q33331826 | R-hirudin as anticoagulant in regular hemodialysis therapy: finding of therapeutic R-hirudin blood/plasma concentrations and respective dosages |
| Q82630332 | R-hirudin for cardiopulmonary bypass |
| Q76693111 | RESEARCH ON THE ANTICOAGULANT AND FIBRINOLYTIC ACTION IN VIVO OF HIRUDIN |
| Q92712521 | RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection |
| Q67837890 | Radioimmunoassay for for the detection of active-site specific thrombin inhibitors in biological fluids. I. Assay characteristics and quantitation of recombinant hirudin |
| Q67837894 | Radioimmunoassay for the detection of active-site specific thrombin inhibitors in biological fluids. II. Heparin affects the binding of hirudin to alpha-thrombin |
| Q72112501 | Radiolabeled r-hirudin as a measure of thrombin activity at, or within, the rabbit aorta wall in vitro and in vivo |
| Q72711401 | Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators |
| Q64914959 | Randomized, double-blind, placebo-controlled, interventional phase IV investigation to assess the efficacy and safety of r-hirudin gel (1120I.U) in patients with hematomas. |
| Q67227231 | Rapid Molecular Weight Determination of Recombinant Hirudin by Matrix-assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry |
| Q43686309 | Rapid purification and revised amino-terminal sequence of hirudin: a specific thrombin inhibitor of the bloodsucking leech. |
| Q40591986 | Rational design of stable and functional hirudin III mutants with lower antigenicity |
| Q71106657 | Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors |
| Q71514857 | Rational design, recombinant preparation, and in vitro and in vivo characterization of human prothrombin-derived hirudin antagonists |
| Q33332776 | Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia. |
| Q74205842 | Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to |
| Q71827441 | Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina |
| Q71875422 | Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction |
| Q36702893 | Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism |
| Q63101860 | Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis |
| Q33330590 | Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. |
| Q73081781 | Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial |
| Q33504870 | Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study |
| Q70840841 | Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis) |
| Q67830294 | Recombinant hirudin and its analogs--new perspectives in antithrombotic treatment |
| Q28374015 | Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia |
| Q71873381 | Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man |
| Q71683207 | Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris |
| Q33333084 | Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients |
| Q42656025 | Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model |
| Q73374631 | Recombinant hirudin as anticoagulant during cardiopulmonary bypass |
| Q47293071 | Recombinant hirudin compared with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement |
| Q44725082 | Recombinant hirudin displaces human factor Xa from its endothelial binding sites |
| Q44999354 | Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model |
| Q33375471 | Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study |
| Q33329312 | Recombinant hirudin for extended aortic surgery in patients with heparin-induced thrombocytopenia |
| Q71025487 | Recombinant hirudin for prevention of experimental postoperative intraocular fibrin |
| Q53466513 | Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. |
| Q72344112 | Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial |
| Q33336308 | Recombinant hirudin in clinical practice: focus on lepirudin. |
| Q33338275 | Recombinant hirudin in neurosurgery |
| Q72560551 | Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters |
| Q73452850 | Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery |
| Q73426604 | Recombinant hirudin is a heparin alternative in cardiac surgery |
| Q73180183 | Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery |
| Q35543460 | Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells |
| Q31160139 | Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo |
| Q43224433 | Recombinant hirudin, a new anticoagulant, has no effect on faecal blood loss |
| Q67976042 | Recombinant hirudin--initial observations in reconstructive microsurgery |
| Q37527940 | Recombinant hirudin: a new prospect in thrombosis |
| Q49110466 | Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis |
| Q33377514 | Recombinant hirudin: clinical pharmacology and potential applications in nephrology |
| Q36917056 | Recombinant hirudin: genetic engineering and structure analysis |
| Q67922817 | Recombinant hirudin: kinetic mechanism for the inhibition of human thrombin |
| Q73168756 | Reduction in vascular lesion formation by hirudin secreted from retrovirus-transduced confluent endothelial cells on vascular grafts in baboons |
| Q45964651 | Reduction of adhesion formation by intraperitoneal administration of a recombinant Hirudin analog. |
| Q82275437 | Reduction of r-hirudin induced bleeding in pigs by the administration of von Willebrand factor |
| Q73627413 | Reevaluating the effects of tyrosine iodination of recombinant hirudin on its thrombin inhibition kinetics |
| Q34345404 | Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin |
| Q27653704 | Refined structure of the hirudin-thrombin complex |
| Q68192939 | Refinement of the thrombin-bound structure of a hirudin peptide by a restrained electrostatically driven Monte Carlo method |
| Q45862700 | Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins |
| Q33341876 | Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis |
| Q67826280 | Reocclusion after thrombolysis: a problem solved by hirudin? |
| Q33341276 | Repetitive intraoperative use of recombinant hirudin (Lepirudin) in peripheral vascular surgery with HITT. |
| Q67824087 | Report on a Discussion Forum: “Medical and Surgical Application of Recombinant Hirudin” |
| Q45859676 | Retroviral vector-mediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins |
| Q72546800 | Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate |
| Q34357549 | Robust preparative-scale extracellular production of hirudin in Escherichia coli and its purification and characterization |
| Q82348193 | Role of Hirudin-like factor Va heavy chain sequences in prothrombinase function |
| Q68000629 | Role of interactions involving C-terminal nonpolar residues of hirudin in the formation of the thrombin-hirudin complex |
| Q44148925 | Role of recombinant hirudin in a pig-to-human lung transplantation model |
| Q41922890 | Role of the acidic hirudin-like COOH-terminal amino acid region of factor Va heavy chain in the enhanced function of prothrombinase |
| Q33378329 | Rotational thrombelastometry for the bedside monitoring of recombinant hirudin |
| Q42157183 | STUDIES IN EXPERIMENTAL EXTRACORPOREAL THROMBOSIS : III. EFFECTS OF CERTAIN ANTICOAGULANTS (HEPARIN AND HIRUDIN) ON EXTRACORPOREAL THROMBOSIS AND ON THE MECHANISM OF THROMBUS FORMATION. |
| Q72560573 | Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty |
| Q43810060 | Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) |
| Q41683583 | Secretion of biologically active leech hirudin from baculovirus-infected insect cells |
| Q37396961 | Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons |
| Q100511893 | Self-regulated hirudin delivery for anticoagulant therapy |
| Q58245110 | Sensitively Detecting Recombinant Hirudin Variant-2 with Capacitive Immunoassay Based on Self-Assembled Monolayers |
| Q72279664 | Separation of r-hirudin from similar substances by capillary electrophoresis |
| Q54249569 | Sequence-specific deamidation: isolation and biochemical characterization of succinimide intermediates of recombinant hirudin. |
| Q73100054 | Serious bleeding in a haemodialysis patient treated with recombinant hirudin |
| Q54423385 | Site specific radioiodination of recombinant hirudin. |
| Q47347182 | Size of Hirudin Sequence Required To Fold into an Active Core Domain |
| Q38756913 | Soluble Expression of a Human MnSOD and Hirudin Fusion Protein in Escherichia coli, and Its Effects on Metastasis and Invasion of 95-D Cells |
| Q64410508 | Solution structure of recombinant hirudin and the Lys-47 .fwdarw. Glu mutants: a nuclear magnetic resonance and hybrid distance geometry-dynamical simulated annealing study |
| Q27697974 | Solution structure of recombinant hirudin and the Lys-47----Glu mutant: a nuclear magnetic resonance and hybrid distance geometry-dynamical simulated annealing study |
| Q37305569 | Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin |
| Q37012366 | Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty |
| Q98419873 | Specific-site PEGylation of Hirudin on Ion-exchange Column and Theoretical Prediction and Analysis of Modified Sites by Molecular Dynamics Simulation |
| Q44452233 | Specificity determinants for tyrosine protein kinase. A study with recombinant hirudin mutants |
| Q61668832 | Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period |
| Q43776332 | Stability of hirudin, a thrombin-specific inhibitor. The structure of alkaline-inactivated hirudin |
| Q43653610 | Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors |
| Q73012297 | State of aggregation of recombinant hirudin in solution under physiological conditions |
| Q73704758 | Stroke risk with higher heparin, hirudin dosages halts studies |
| Q87239577 | Structural and Functional Characterization of Hirudin P6 Derived Novel Bivalent Thrombin Inhibitors - Studying the Effect of Linker Length and Glycosylation on Their Function |
| Q35005006 | Structural basis of RGD-hirudin binding to thrombin: Tyr3 and five C-terminal residues are crucial for inhibiting thrombin activity |
| Q67507223 | Structural differences in active site-labeled thrombin complexes with hirudin isoinhibitors |
| Q67826278 | Structure - function relationships of the C-terminal functional domain of hirudin and its variants |
| Q82455729 | Structure study of recombinant RGD-hirudin by vibrational and circular dichroism spectroscopy |
| Q71689390 | Structure-activity studies on C-terminal hirudin peptides containing sulfated tyrosine residues |
| Q67976048 | Structure-function and refolding studies of the thrombin-specific inhibitor hirudin |
| Q67688147 | Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons |
| Q69711793 | Studies on antithrombotic effects of recombinant hirudin |
| Q39272446 | Studies on platelet functions in hirudin plasma |
| Q46659181 | Studies on the nasal epithelium toxicity of adjuvants and recombination hirudin (rHV2) nasal spary |
| Q70665002 | Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs |
| Q54139903 | Studies on the pharmacokinetics of hirudin. |
| Q63240648 | Subcutaneous infusion of r-hirudin does not inhibit neointimal proliferation after angioplasty of the subclavian artery in cholesterol-fed rabbits |
| Q53360004 | Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group. |
| Q73264459 | Successful anticoagulation with hirudin in a patient with mesenteric venous thrombosis and multiple coagulation abnormalities |
| Q33370351 | Successful renal transplantation in a patient with heterozygous prothrombin gene, factor V Leiden mutation and heparin-induced thrombocytopenia using r-hirudin as anticoagulant |
| Q46594735 | Successful treatment of mesenterial venous thrombosis with recombinant hirudin--a report of five cases |
| Q33396431 | Successful use of hirudin during cardiac surgery using minimized extracorporeal circulation in patients with heparin-induced thrombocytopenia |
| Q73013631 | Successful use of low dose r-hirudin (Refludan) for recurrent dialysis catheter thrombosis in a patient with heparin induced thrombocytopenia |
| Q33364678 | Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization |
| Q57713301 | Sulphation of hirudin in BHK cells |
| Q71670462 | Surface adsorption and fibrinogen interactions with hirudin-thrombin complex |
| Q51622467 | Surface characterization and platelet adhesion studies on polyethylene surface with hirudin immobilization. |
| Q37779990 | Surface modification with PEG and hirudin for protein resistance and thrombin neutralization in blood contact. |
| Q68009736 | Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin |
| Q69763911 | Sustained bleeding after a leech bite in the apparent absence of hirudin |
| Q47883558 | Sustained release of injectable zinc-recombinant hirudin suspensions: development and validation of in vitro release model |
| Q41025253 | Synthesis and characterization of a recombinant hirudin-albumin complex |
| Q77349735 | Synthesis and characterization of more potent analogues of hirudin fragment 1-47 containing non-natural amino acids |
| Q67527742 | Synthesis and secretion of hirudin by Streptomyces lividans |
| Q47406768 | Synthesis of a homologous series of ketomethylene arginyl pseudodipeptides and application to low molecular weight hirudin-like thrombin inhibitors |
| Q71689398 | Synthesis of peptide p-nitroanilides mimicking fibrinogen- and hirudin-binding to thrombin. Design of slow reacting thrombin substrates |
| Q34232126 | Systematic Review of Hirudin in Acute Coronary Syndromes and Percutaneous Coronary Intervention |
| Q30828130 | Systematic study of the substituted active C-terminus of hirudin |
| Q48654048 | Test of hirudin activity by tracking the binding of hirudin to thrombin in the presence of BS3 cross-linking |
| Q47105710 | The Anti-Coagulant Action of Hirudin |
| Q45226893 | The C-terminal binding domain of hirullin P18. Antithrombin activity and comparison to hirudin peptides |
| Q52475064 | The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen. |
| Q36917044 | The Comeback of Hirudin as an Antithrombotic Agent |
| Q27646281 | The NMR solution structure of recombinant RGD-hirudin |
| Q80326147 | The action of hirudin upon thrombin |
| Q54544854 | The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. |
| Q72595363 | The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models |
| Q84253324 | The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits |
| Q32043322 | The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels |
| Q44040866 | The beginnings of hirudin |
| Q44518890 | The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model |
| Q38192900 | The comeback of hirudin--an old-established anticoagulant agent |
| Q68837648 | The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits |
| Q70477495 | The complete amino acid sequence of a hirudin variant from the leech Hirudinaria manillensis |
| Q56638594 | The complete amino acid sequence of hirudin, a thrombin specific inhibitor |
| Q49239525 | The complete covalent structure of hirudin. Localization of the disulfide bonds |
| Q33928860 | The conformations of hirudin in solution: a study using nuclear magnetic resonance, distance geometry and restrained molecular dynamics. |
| Q71754955 | The core domain of hirudin from the leech Hirudinaria manillensis. Chemical modification of a tryptophan-containing synthetic peptide analog |
| Q33468707 | The determination of platelet factor 3 using hirudin |
| Q40670893 | The development of hirudin as an antithrombotic drug |
| Q71699515 | The diagnostic capability of thrombelastogram, heparin and hirudin tolerance tests during anticoagulant therapy |
| Q33379453 | The direct thrombin inhibitor hirudin |
| Q70500547 | The disulfide folding pathway of hirudin elucidated by stop/go folding experiments |
| Q50166330 | The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits |
| Q47679867 | The effect of anticoagulation with subcutaneously delivered polyethylene glycol conjugated hirudin and recombinant tissue plasminogen activator on recurrent stenosis in the rabbit double-balloon injury model. |
| Q33441048 | The effect of hirudin modification of silk fibroin on cell growth and antithrombogenicity |
| Q64115658 | The effect of hirudin on antagonisting thrombin induced apoptosis of human microvascular endothelial cells1 |
| Q71380997 | The effect of hirudin on endotoxin induced disseminated intravascular coagulation (DIC) |
| Q44114225 | The effect of hirudin therapy on certain functions and hydrodynamics of the eye in patients with glaucoma |
| Q80321864 | The effect of hirudin upon the gases in arterial blood |
| Q71863931 | The effect of hirudin, a potent antithrombin, on the thromboplastin generation test |
| Q46104056 | The effect of local application of natural hirudin on random pattern skin flap microcirculation in a porcine model |
| Q74073826 | The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis |
| Q40737806 | The effect of recombinant hirudin on arterial thrombosis |
| Q35199933 | The effect of recombinant hirudin on rabbit ear flaps with venous insufficiency |
| Q58037584 | The effect of substituting phosphotyrosine for sulphotyrosine on the activity of hirudin |
| Q92567625 | The effects of a hirudin/liposome complex on a diabetic nephropathy rat model |
| Q91305777 | The effects of overexpression of cytoplasmic chaperones on secretory production of hirudin-PA in E. coli |
| Q33378583 | The effects of recombinant hirudin on various platelet functions |
| Q33333313 | The emergency use of recombinant hirudin in cardiopulmonary bypass. |
| Q33369557 | The emergency use of recombinant hirudin in cardiopulmonary bypass. 1999. |
| Q33279630 | The folding of hirudin adopts a mechanism of trial and error |
| Q70458912 | The functional domain of hirudin, a thrombin-specific inhibitor |
| Q47348679 | The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin |
| Q68598986 | The hirudin standard |
| Q78835245 | The hirudin tolerance test |
| Q69190836 | The hirudin-binding site of human alpha-thrombin. Identification of lysyl residues which participate in the combining site of hirudin-thrombin complex |
| Q94504053 | The hirudin-like factors HLF3 and HLF4-hidden hirudins of European medicinal leeches |
| Q47328569 | The history of leeching and hirudin |
| Q68579429 | The influence of GAP promoter variants on hirudin production, average plasmid copy number and cell growth in Saccharomyces cerevisiae |
| Q77500060 | The influence of hirudin on plasma fibrinogen assays |
| Q67987309 | The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro |
| Q71198739 | The inhibition of the intrinsic generation of activated factor X by heparin and hirudin |
| Q44842366 | The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma |
| Q42796533 | The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin |
| Q44266085 | The medicinal leech Hirudo medicinalis: clinical use of the animal and therapeutic prospects of hirudin |
| Q68900477 | The pharmacology of recombinant hirudin, a new anticoagulant |
| Q77747933 | The platelet high affinity binding site for thrombin mimics hirudin, modulates thrombin-induced platelet activation, and is distinct from the glycoprotein Ib-IX-V complex |
| Q35806499 | The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes |
| Q68254346 | The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity |
| Q33337908 | The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery |
| Q67919646 | The role of endothelium in factor Xa regulation: the effect of plasma proteinase inhibitors and hirudin |
| Q41809921 | The stabilization and release of hirudin from liposomes or lipid-assemblies coated with hydrophobically modified dextran |
| Q67275722 | The structural elements of hirudin which bind to the fibrinogen recognition site of thrombin are exclusively located within its acidic C-terminal tail |
| Q68033746 | The structure of a complex of bovine alpha-thrombin and recombinant hirudin at 2.8-A resolution |
| Q27684792 | The structure of a complex of recombinant hirudin and human alpha-thrombin |
| Q73226945 | The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure |
| Q71418832 | The thrombin inhibitor, hirudin, attenuates lipopolysaccharide-induced liver injury in the rat |
| Q83205817 | The thrombin inhibitors hirudin and Refludan(®) activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets |
| Q82897472 | The use of PEG-Hirudin in chronic hemodialysis monitored by the Ecarin Clotting Time: influence on clotting of the extracorporeal system and hemostatic parameters |
| Q43858772 | The use of hirudin as universal anticoagulant in haematology, clinical chemistry and blood grouping |
| Q74519142 | The use of intravenous recombinant hirudin in the treatment of deep vein thrombosis in a patient with an acute heparin allergy |
| Q92110862 | Therapeutic effects of the rhSOD2-Hirudin fusion protein on bleomycin-induced pulmonary fibrosis in mice |
| Q67481671 | Therapeutic levels of recombinant hirudin |
| Q41649839 | Thermodynamic investigation of hirudin binding to the slow and fast forms of thrombin: evidence for folding transitions in the inhibitor and protease coupled to binding |
| Q73681259 | Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023) |
| Q74554108 | Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery |
| Q67826271 | Thrombin inhibition by covalently bound hirudin |
| Q37305532 | Thrombin inhibition by hirudin: how hirudin inhibits thrombin |
| Q67257535 | Thrombin inhibition by synthetic hirudin peptides |
| Q38735166 | Thrombin interactions with hirudin |
| Q72544903 | Thrombin-Hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma |
| Q68809156 | Thrombin-bound conformation of the C-terminal fragments of hirudin determined by transferred nuclear Overhauser effects |
| Q67840408 | Thrombin-hirudin complex stability: a comparison with the thrombin-antithrombin III complex |
| Q54192122 | Thrombin-induced aggregation of lymphocytes: non-enzymic induction by an hirudin-blocked thrombin exosite. |
| Q49375827 | Time dependent reduction in platelet aggregation using the multiplate analyser and hirudin blood due to platelet clumping |
| Q35116875 | Total synthesis of homogeneous variants of hirudin P6: a post-translationally modified anti-thrombotic leech-derived protein. |
| Q69041724 | Toxicological studies with recombinant hirudin |
| Q36916987 | Toxicology of hirudin |
| Q92597003 | Transcriptomic Analysis of the Influence of Methanol Assimilation on the Gene Expression in the Recombinant Pichia pastoris Producing Hirudin Variant 3 |
| Q72103048 | Transient hydrogen bonds identified on the surface of the NMR solution structure of Hirudin |
| Q33332053 | Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin |
| Q33373086 | Treatment of hirudin overdosage in a dialysis patient with heparin-induced thrombocytopenia with mixed hemodialysis and hemofiltration treatment. |
| Q74578714 | Treatment of hirudin overdosage in a patient with chronic renal failure |
| Q72653458 | Treatment of severe venous thrombo-embolism with intravenous Hirudin (HBW 023): an open pilot study |
| Q46590525 | Triple-coated stents (Hirudin/Iloprost/Paclitaxel): an in vitro approach for characterizing the antiproliferative potential of each individual compound |
| Q51789130 | Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity. |
| Q71622030 | Two-site immunoassay of recombinant hirudin based on two monoclonal antibodies |
| Q45102884 | Type I and Type IV allergy to unfractionated heparin and low-molecular-weight heparin with no reaction to recombinant hirudin |
| Q64911825 | Type IV allergy to natural hirudin confirmed by in vitro stimulation with recombinant hirudin. |
| Q73484688 | Unfolding of hirudin characterized by the composition of denatured scrambled isomers |
| Q67013543 | Use of N-benzoyl-phenylalanyl-valyl-arginine p-nitroanilide and hirudin for the detection of enzymatic activity under prothrombin acylation by citraconic anhydride |
| Q68499275 | Use of fragments of hirudin to investigate thrombin-hirudin interaction |
| Q74536197 | Use of recombinant hirudin as an anticoagulant in plasmapheresis in a patient with heparin-induced thrombocytopenia |
| Q33489102 | Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia |
| Q33183031 | Use of recombinant hirudin in heparin-induced thrombocytopenia and thrombosis (HITT) and renal failure--a case report |
| Q28368823 | Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass |
| Q52480931 | Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit model. |
| Q33333125 | Use of recombinant-hirudin in pulmonary thromboendarterectomy |
| Q54743556 | Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. |
| Q54021999 | Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group). |
| Q78848621 | [A novel high quality specific antithrombotic drug--hirudin] |
| Q72992839 | [A novel hirudin coating of vascular endoprostheses: experimental results] |
| Q31058038 | [Absorption of recombinant hirudin in rats GI tract]. |
| Q91787684 | [Antithrombotic effects of recombinant hirudin in mice and its mechanism] |
| Q70198885 | [Biochemical and pharmacological aspects of the thrombin inhibitor hirudin] |
| Q73391503 | [Biological activity of pharmacological properties of the anticoagulant complex (hirudin, plasma kallikrein inhibitor, prostaglandin) from the leech Hirudo medicinalis] |
| Q84571151 | [Biotechnological production of recombinant analogs of hirudin-1 from Hirudo medicinalis] |
| Q72630411 | [Comeback of the leech. Recombinant hirudin in anti-thrombosis therapy] |
| Q71233566 | [Comparative properties of hirudin from whole leeches and from leech heads and bodies] |
| Q71206974 | [Comparative study of preparations of hirudin and "pseudohirudin"] |
| Q54641891 | [Construction and expression of a fusion protein made of tissue-type plasminogen activator and hirudin in Pichia pastoris]. |
| Q76419812 | [Contributions to the diagnosis of blood coagulation disorders and on the supervision of anticoagulant therapy with the aid of hirudin.] |
| Q77812077 | [Decolorization and isolation of recombinant hirudin expressed in the methylotrophic yeast Pichia pastoris] |
| Q79688461 | [Degradation of recombinant hirudin-2 in nasal mucosa of rabbits in vitro] |
| Q95395847 | [Determination of recombinant hirudin in urine of rat by spectrophotometric method] |
| Q72906825 | [Determination of the molecular weight of hirudin in the ultracentrifuge] |
| Q74552311 | [Determination of thrombin by titration with hirudin] |
| Q95354365 | [Effect and mechanism of recombinant hirudin on atherosclerotic plaques in apolipoprotein E knockout (ApoE(-/-)) mice] |
| Q79367219 | [Effect and mechanism of recombinant hirudin on fibrinolysis] |
| Q84053412 | [Effect of hirudin on random skin flap survival in rats] |
| Q70820857 | [Effect of hirudin-thrombin and phenylmethylsulfonyl-thrombin on various blood clotting indices] |
| Q84585774 | [Effect of local injection of recombinant hirudin on survival of skin flaps with venous congestion in a rabbit model] |
| Q90658047 | [Effect of natural hirudin on angiogenesis of human microvascular endothelial cells] |
| Q90340843 | [Effect of natural hirudin on revascularization of ischemic skin flaps in rats by Micro-CT] |
| Q79475237 | [Effects of fusion gene encoding the hVEGF165 and fused hirudin on restenosis of injured carotid artery induced by angioplasty] |
| Q53543280 | [Effects of hirudin on the expression of basic fibroblast growth factor and transforming growth factor-β1 in human gingival fibroblasts]. |
| Q85890416 | [Emulsion liquid membrane extraction with D2EHPA mobile carrier Hirudinaria manillensis hirudin in experimental study] |
| Q84967953 | [Experimental study on effect of hirudin in inhibiting hyperplastic scar fibroblasts] |
| Q82895361 | [Experimental study on effect of natural hirudin on vein congestion of random skin flap in porcine models] |
| Q76246406 | [Experimental study on the effect of hirudin on the factors of blood coagulation.] |
| Q78487701 | [Experiments on the pharmacological characterization of hirudin.] |
| Q77079470 | [Experiments on the reaction mechanisms of hirudin] |
| Q73596882 | [Expression and purification of recombinant hirudin] |
| Q81081243 | [Fermentation, purification and identification of recombinant RGD-Hirudin] |
| Q80224685 | [From fibrinogen and hirudin to synthetic anticoagulants. Rational design of thrombin inhibitors] |
| Q76423491 | [Hemostasis insufficiency in thrombin blockade by Hirudin.] |
| Q53839951 | [Hirudin and other thrombin inhibitors from blood-sucking animals] |
| Q77388738 | [Hirudin for heparin-induced thrombopenia: a new step forward] |
| Q67245356 | [Hirudin inhibition of human thrombin activity] |
| Q67909394 | [Hirudin therapy and blood coagulability] |
| Q73201557 | [Hirudin: the relative failure of a very promising molecule] |
| Q77192603 | [Hirudin; an inhibitor of blood coagulation from medical leeches] |
| Q74058378 | [In AT-III deficiency: heparin or hirudin?] |
| Q74652077 | [Isolation and chemical characterization of hirudin] |
| Q53885768 | [On the evolution of endopeptidases. VI. Specific inhibition by hirudin of proteases from vertebrates and invertebrates] |
| Q68429343 | [On the presence of a trypsin-plasmin inhibitor in hirudin] |
| Q77388743 | [Once upon a time there was hirudin...]. |
| Q95501712 | [Preparation of freeze-dried powder of recombinate hirudin-2 nanoparticle for nasal delivery and permeability through nasal membrane in vitro] |
| Q78847715 | [Progress in the controlled release systems of hirudin] |
| Q53631592 | [Protective effects of hirudin on acute experimental intracerebral hemorrhage]. |
| Q79539876 | [Purification of hirudin.] |
| Q78228034 | [Quantitative determination of prothrombin by titration with hirudin.] |
| Q80299784 | [Research progress in hirudin fusion protein--review] |
| Q74104556 | [Studies on hirudin] |
| Q80638678 | [Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats] |
| Q74342146 | [Studies on the mechanism of the anticoagulant effect of hirudin] |
| Q72921297 | [Study of certain physicochemical constants of hirudin] |
| Q71558331 | [Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis. A pharmacokinetic study] |
| Q77215174 | [Synthesis of hirudin variant 1 (HV1) gene and primary study of expression in yeast] |
| Q74037161 | [Technical improvements in genetic manipulation of Pichia pastoris and their application in hirudin expression] |
| Q79412260 | [The hirudin test, a micromethod for control of the prothrombin level in anticoagulant therapy] |
| Q77867869 | [The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins] |
| Q83943083 | [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray] |
| Q69133744 | [The pharmacology of recombinant hirudin] |
| Q73266121 | [The practical value of the hirudin test in vitro] |
| Q78425990 | [The reaction between hirudin and thrombin.] |
| Q72788139 | [The significance of the hirudin tolerance test for the differentiation of hemorrhagic disorders in pediatrics] |
| Q79068158 | [The use of prothrombin determination with hirudin in the supervision of treatment with dicoumarol derivatives] |
| Q70261863 | [The use of the specific thrombin inhibitor hirudin in diagnostic and biochemical studies] |
| Q73038813 | [Therapy of acute coronary syndrome. Aspirin, heparin, low-molecular-weight heparin, hirudin and GP-IIb/IIIa blockers] |
| Q93693805 | [Use of hirudin in clinical coagulation laboratories] |
| Q67741650 | pH Dependence of the interaction of hirudin with thrombin |
| Q77474773 | r-Hirudin for percutaneous coronary interventions--time to reconsider? |
| Q77618915 | r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons |
| Q43842217 | r-hirudin as anticoagulant for cardiopulmonary bypass |
| Q36788973 | r-hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study |
| Q57095961 | Über Hirudin |
| Q56638593 | Untersuchungen �ber Hirudin |
| uri / http://www.wikidata.org/entity/L1172305-S1 | L1172305-S1 | item for this sense | P5137 |
| Category:Hirudin | wikimedia | |
| Гірудзін | wikipedia | |
| bn | হিরুডিন | wikipedia |
| Hirudin | wikipedia | |
| Hirudin | wikipedia | |
| Hirudin | wikipedia | |
| Hirudina | wikipedia | |
| Persian (fa / Q9168) | هیرودین | wikipedia |
| Hirudiini | wikipedia | |
| Hirudine | wikipedia | |
| Hirudin | wikipedia | |
| Hirudin | wikipedia | |
| Հիրուդին | wikipedia | |
| Hirudin | wikipedia | |
| Irudina | wikipedia | |
| ヒルジン | wikipedia | |
| 히루딘 | wikipedia | |
| mk | Хирудин | wikipedia |
| ml | ഹിരുഡിൻ | wikipedia |
| Hirudine | wikipedia | |
| Hirudyna | wikipedia | |
| Hirudina | wikipedia | |
| Hirudină | wikipedia | |
| Гирудин | wikipedia | |
| Hirudin | wikipedia | |
| Хирудин | wikipedia | |
| Гірудин | wikipedia | |
| 水蛭素 | wikipedia |
Search more.